BMS-754807 + cetuximab

BMS-754807 + cetuximab is an experimental combination therapy composed of **BMS-754807**, a potent and reversible small molecule inhibitor of **insulin-like growth factor 1 receptor (IGF-1R)** and the **insulin receptor (InsR)** family kinases, and **cetuximab** (marketed as Erbitux), a chimeric monoclonal antibody targeting the **epidermal growth factor receptor (EGFR)**. Preclinical and early clinical studies indicate that this combination can produce synergistic anti-proliferative effects and improved tumor control compared to monotherapy, likely due to the dual blockade of IGF-1R/InsR and EGFR signaling pathways critical for tumor proliferation and survival. BMS-754807 has been investigated in a range of tumor types, including epithelial and mesenchymal cancers, while cetuximab is an approved therapy for certain colorectal and head and neck cancers[1][4][5].

Other names

BMS-754807 + Erbitux